Advent-Morro Equity Partners

Advent-Morro Equity Partners is a venture capital firm founded in 1989 and based in San Juan, Puerto Rico. The firm specializes in investing in companies across various sectors, including healthcare, telecommunications, distribution, technology services, education, and hospitality. As a Registered Investment Adviser, Advent-Morro Equity Partners is dedicated to identifying and supporting growth opportunities within these industries, leveraging its expertise to enhance the value of its investments.

Cyril Meduna

Founder and Managing Partner

9 past transactions

Ole Insurance Group

Series B in 2025
Ole Insurance Group focuses on offering protection and well-being products and services through technology. Ole Insurance Group was founded in 2021 and was headquartered in Puerto Rico.

Kiwi

Funding Round in 2023
Kiwi is a financial technology company founded in 2020 and based in San Juan, Puerto Rico. It offers an application aimed at promoting financial inclusion by providing users with access to affordable capital. The app facilitates quick account creation with rapid identity verification and allows users to report their loan payment behavior to major credit bureaus. This functionality helps users build their credit scores, enabling them to obtain unsecured loans and credit builder loans. Additionally, Kiwi focuses on enhancing financial literacy, making it a valuable resource for individuals seeking to improve their financial well-being.

Hyperion

Angel Round in 2022
Hyperion is an all-in-one finance app that integrates essential financial services for small businesses through a mobile application. Hyperion’s customers can validate a business in minutes, having access to cash management, B2B payments, financial reports, and a business network they can tap into.

Kiwi

Seed Round in 2022
Kiwi is a financial technology company founded in 2020 and based in San Juan, Puerto Rico. It offers an application aimed at promoting financial inclusion by providing users with access to affordable capital. The app facilitates quick account creation with rapid identity verification and allows users to report their loan payment behavior to major credit bureaus. This functionality helps users build their credit scores, enabling them to obtain unsecured loans and credit builder loans. Additionally, Kiwi focuses on enhancing financial literacy, making it a valuable resource for individuals seeking to improve their financial well-being.

Quench

Venture Round in 2014
Quench USA, Inc. offers Water-as-a-Service(TM) solutions by providing bottleless filtered water coolers and other products that use filtered water as an input, such as ice machines, sparkling water dispensers, and coffee brewers, to customers across the United States. Our point-of-use (POU) systems purify a building's existing water supply to provide reliable and convenient filtered water to a broad mix of end-markets, including government, education, medical, manufacturing, retail, hospitality, and other large commercial customers, including more than half of the Fortune 500. Headquartered outside of Philadelphia, Quench recently became an independent operating company of AquaVenture Holdings(TM).

Quench

Venture Round in 2011
Quench USA, Inc. offers Water-as-a-Service(TM) solutions by providing bottleless filtered water coolers and other products that use filtered water as an input, such as ice machines, sparkling water dispensers, and coffee brewers, to customers across the United States. Our point-of-use (POU) systems purify a building's existing water supply to provide reliable and convenient filtered water to a broad mix of end-markets, including government, education, medical, manufacturing, retail, hospitality, and other large commercial customers, including more than half of the Fortune 500. Headquartered outside of Philadelphia, Quench recently became an independent operating company of AquaVenture Holdings(TM).

Seven Seas Water

Venture Round in 2008
Seven Seas Water Corporation is a multinational company specializing in outsourced water treatment, wastewater treatment, and reuse solutions for a diverse range of clients, including governmental, municipal, industrial, property developers, and hospitality sectors. Founded in 1996 and headquartered in Tampa, Florida, the company operates over 150 water and wastewater treatment plants across the United States, Caribbean, and Latin America. Seven Seas Water offers a comprehensive Water-as-a-Service model that includes custom desalination, advanced water treatment, and emergency water supplies. The firm is involved in both the development of new treatment facilities and the acquisition of existing operations, showcasing its capabilities in project execution and risk management. Through advanced technologies like seawater reverse osmosis, Seven Seas Water aims to provide cost-effective and sustainable water solutions, ensuring a reliable supply of potable and industrial process water for its clients.

AquaVenture Holdings

Series A in 2007
AquaVenture Holdings is a water purification company based in Tampa, Florida, founded in 2006. It operates through two main divisions: Quench and Seven Seas Water. The company specializes in providing water solutions, including water purification and desalination services, primarily serving clients in the service industry and the British Virgin Islands. AquaVenture Holdings focuses on delivering reliable and cost-effective sources of clean drinking and process water, helping clients ensure safe drinking water and improved sanitation for their families and communities.

Bioheart

Venture Round in 2005
Bioheart, Inc. is dedicated to advancing the field of regenerative medicine by offering the highest quality technology, cellular treatments and training. Specific to biotechnology, Bioheart, Inc. specializes in the discovery, development and commercialization of autologous cellular therapies that treat a wide variety of degenerative diseases. Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry by delivering stem cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions, chronic and acute heart damage, peripheral vascular disease and other issues. Bioheart's goals are to improve a patient’s quality of life by regenerating their damaged tissue, when possible, and by reducing health care costs and hospitalizations. Bioheart’s leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.